Rab L3 Inhibitors
To inhibit Rab L3, several classes of inhibitors can be considered. Farnesyltransferase inhibitors (FTIs) like FTI-277 and geranylgeranyltransferase inhibitors (GGTIs) such as GGTI 298 can prevent the prenylation of Rab L3, thereby disrupting its membrane targeting and inhibiting its regulatory role in KRAS signaling and cell proliferation modulation. BMS 214662, a selective inhibitor of Rab geranylgeranyltransferase (RabGGTase), can specifically inhibit the prenylation of Rab proteins, including Rab L3. Indirect inhibitors can also be utilized to influence the pathways in which Rab L3 is involved. Compounds like GDC-0032, Selumetinib, PD 0325901, U0126, LY 294002, AZD6244, SCH772984, PD173074, and Sorafenib target key components of the KRAS signaling pathway, such as PI3K, AKT, MEK, ERK, and FGFR. By inhibiting these downstream effectors or upstream kinases, these compounds can impact the regulation of KRAS signaling and affect the function of Rab L3, leading to the modulation of cell proliferation.
In summary, Rab L3 inhibitors can target the prenylation process directly, inhibiting the attachment of lipid groups to Rab proteins. Additionally, inhibitors of key components in the KRAS signaling pathway can indirectly influence the function of Rab L3 by disrupting the signaling cascade. These inhibitors have the ability to provide valuable insights into the role of Rab L3 in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
GGTI 298 is a geranylgeranyltransferase inhibitor that specifically inhibits the geranylgeranylation of small GTPases, including Rab L3. By blocking the geranylgeranylation process, GGTI 298 prevents the proper membrane targeting and activity of Rab L3, leading to the inhibition of its role in KRAS signaling regulation and cell proliferation modulation. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a selective inhibitor of AKT, a downstream effector of KRAS signaling. By inhibiting AKT, AZD5363 can indirectly influence the regulation of KRAS signaling and potentially impact the function of Rab L3 in this pathway, leading to modulation of cell proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K, a key regulator of the PI3K/AKT pathway involved in KRAS signaling. By inhibiting PI3K, LY 294002 indirectly affects the regulation of KRAS signaling and can potentially impact the function of Rab L3 in this pathway, leading to modulation of cell proliferation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a selective inhibitor of MEK1 and MEK2, which are upstream kinases in the MAPK pathway. By inhibiting MEK, Selumetinib indirectly influences the regulation of KRAS signaling and can potentially impact the function of Rab L3 in this pathway, leading to modulation of cell proliferation. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $363.00 | 5 | |
SCH772984 is a selective inhibitor of ERK1/2, downstream effectors of the MAPK pathway involved in KRAS signaling. By inhibiting ERK1/2, SCH772984 indirectly affects the regulation of KRAS signaling and can potentially impact the function of Rab L3 in this pathway, leading to modulation of cell proliferation. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a selective inhibitor of FGFR, a receptor tyrosine kinase involved in various signaling pathways, including KRAS signaling. By inhibiting FGFR, PD173074 can indirectly influence the regulation of KRAS signaling and potentially impact the function of Rab L3 in this pathway, leading to modulation of cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, VEGFR, PDGFR, and other receptor tyrosine kinases. By inhibiting RAF kinases, Sorafenib indirectly affects the regulation of KRAS signaling and can potentially impact the functionRab L3 (Rab-like protein 3) is a protein involved in the regulation of KRAS signaling and the modulation of cell proliferation. It plays a crucial role in the prenylation of KRAS and other small GTPases, which is essential for their proper membrane localization and activity. Prenylation is the attachment of lipid groups, such as farnesyl or geranylgeranyl, to proteins, enabling their association with cellular membranes. | ||||||